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Maternal and fetal screening
SIR,-We wish to comment on the suggestion by
Dr M J V Bull that a comprehensive serum
TORCH screen (toxoplasmosis, rubella, cyto-
megalovirus, herpes virus) may be appropriate
before conception.' Dr Bull did not discuss the
circumstances in which this might be appropriate
or explore the implications of screening for these
conditions before conception. The acronym
may be a helpful aide memoire for a paediatrician
faced with a sick neonate but is probably less useful
to a general practitioner giving advice to a healthy
woman.
Checking rubella antibody state before concep-
tion is desirable because those who are negative
may be immunised and those who are positive may
be reassured. The action to be taken in the light of
the test result is clear, the possible benefits are
considerable, and the risks are limited largely to
the possibility of inappropriate reassurance to
women who have false positive tests.
A test for antibodies to toxoplasmosis before
conception is less easy to justify. Approximately
80% of women of childbearing age in the United
Kingdom lack evidence of past infection with
toxoplasmosis.2 If the intention is to identify these
women and advise them about ways of avoiding the
infection extending the health education advice
(which is not particularly restrictive) to all women
would be a more efficient use of resources and
would also protect those women who have false
positive results of the screening test.
It is not clear what action should be taken or
advice given after a preconception test for cyto-
megalovirus. About half the women who have
the test will be told that they are susceptible to the
virus and that there is no vaccine. Sexual transmis-
sion is well documented but the risks associated
with close contact with babies and young children,
much debated, are unknown-there is no con-
sensus on specific advice about avoiding cyto-
megalovirus infection.' Fetal damage may
occasionally follow reactivation of infection in
pregnancy, as well as primary infection,4 and thus
reassurance for a woman with a positive test result
may be inappropriate.
Screening for herpes virus is also complicated.
Although primary infection in pregnancy is the
main cause of fetal damage, serious damage may
also follow recurrent infection. Probably only a few
women who have had genital herpes will have had
symptoms that led to diagnosis. Serological tests
discriminating between antibodies to herpes
simplex virus types 1 and 2 are not yet available
routinely -even if they were a growing proportion
of genital infections is now associated with type 1.'
Only about 10% of women have no antibodies to
herpes simplex viruses but probably 90% have not
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had genital herpes and are thus at risk of a primary
infection in pregnancy.6 What useful advice or
reassurance can be given on the basis of knowing a
woman's antibody state?
Doctors should not refuse to test women who are
concerned about particular infections. Never-
theless, the implications of any test, including
difficulties in interpretation, must be discussed
beforehand. But screening is not an appropriate
description of tests undertaken in these circum-
stances -screening is a service offered routinely to
all women in which the advantages of testing
are not outweighed by the disadvantages. It is
unreasonable to offer screening tests for conditions
simply because the tests are available, and it is
extremely unwise to pursue the piecemeal intro-
duction of screening tests before proper evaluation
using recognised criteria.
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